210 related articles for article (PubMed ID: 9934717)
1. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
2. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
3. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Etzioni R; Berry KM; Legler JM; Shaw P
Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
[TBL] [Abstract][Full Text] [Related]
7. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
8. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS
J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964
[TBL] [Abstract][Full Text] [Related]
9. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
10. Trends in prostate cancer mortality among black men and white men in the United States.
Chu KC; Tarone RE; Freeman HP
Cancer; 2003 Mar; 97(6):1507-16. PubMed ID: 12627516
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001.
Sarma AV; Schottenfeld D
Semin Urol Oncol; 2002 Feb; 20(1):3-9. PubMed ID: 11828352
[TBL] [Abstract][Full Text] [Related]
12. Rise and fall of radical prostatectomy rates from 1989 to 1996.
Sheikh K; Bullock C
Urology; 2002 Mar; 59(3):378-82. PubMed ID: 11880074
[TBL] [Abstract][Full Text] [Related]
13. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.
Schwartz KL; Severson RK; Gurney JG; Montie JE
Cancer; 1996 Sep; 78(6):1260-6. PubMed ID: 8826949
[TBL] [Abstract][Full Text] [Related]
14. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.
Feuer EJ; Merrill RM; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1025-32. PubMed ID: 10379965
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
16. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.
Mariotto AB; Etzioni R; Krapcho M; Feuer EJ
Cancer; 2007 May; 109(9):1877-86. PubMed ID: 17372918
[TBL] [Abstract][Full Text] [Related]
17. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
18. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality.
Etzioni R; Legler JM; Feuer EJ; Merrill RM; Cronin KA; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1033-9. PubMed ID: 10379966
[TBL] [Abstract][Full Text] [Related]
19. The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.
Shao YH; Albertsen PC; Shih W; Roberts CB; Lu-Yao GL
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):332-9. PubMed ID: 21709691
[TBL] [Abstract][Full Text] [Related]
20. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]